Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
DGX 
Quest Diagnostics Incorporated (DGX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/31/2025: DGX (1-star) is a SELL. SELL since 2 days. Simulated Profits (-4.27%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
19 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $197.25
1 Year Target Price $197.25
| 8 | Strong Buy |
| 1 | Buy |
| 10 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -11.26% | Avg. Invested days 42 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/31/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 19.57B USD | Price to earnings Ratio 20.65 | 1Y Target Price 197.25 |
Price to earnings Ratio 20.65 | 1Y Target Price 197.25 | ||
Volume (30-day avg) 19 | Beta 0.56 | 52 Weeks Range 146.30 - 197.55 | Updated Date 10/31/2025 |
52 Weeks Range 146.30 - 197.55 | Updated Date 10/31/2025 | ||
Dividends yield (FY) 1.79% | Basic EPS (TTM) 8.52 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-10-21 | When Before Market | Estimate 2.5 | Actual 2.6 |
Profitability
Profit Margin 8.93% | Operating Margin (TTM) 14.92% |
Management Effectiveness
Return on Assets (TTM) 6.12% | Return on Equity (TTM) 14.35% |
Valuation
Trailing PE 20.65 | Forward PE 17.12 | Enterprise Value 26300569883 | Price to Sales(TTM) 1.8 |
Enterprise Value 26300569883 | Price to Sales(TTM) 1.8 | ||
Enterprise Value to Revenue 2.5 | Enterprise Value to EBITDA 12.71 | Shares Outstanding 111242362 | Shares Floating 110657227 |
Shares Outstanding 111242362 | Shares Floating 110657227 | ||
Percent Insiders 0.4 | Percent Institutions 99.34 |
Upturn AI SWOT
Quest Diagnostics Incorporated
Company Overview
History and Background
Quest Diagnostics was founded in 1967 as Metropolitan Pathology Laboratory. In 1969 it was acquired by Bio-Science Laboratories, Inc. In 1982 Corning acquired MetPath and renamed it Corning Clinical Laboratories. In 1996, Corning Clinical Laboratories became Quest Diagnostics, an independent publicly traded company.
Core Business Areas
- Diagnostic Information Services: Provides a broad range of clinical testing services, including routine blood tests, specialized diagnostic assays, and anatomic pathology services. It caters to physicians, hospitals, managed care organizations, employers, and government entities.
Leadership and Structure
As of the last update, Stephen H. Rusckowski serves as Chairman, CEO, and President. The company operates with a traditional corporate structure including a Board of Directors, executive leadership team managing operations, finance, technology, and various business segments.
Top Products and Market Share
Key Offerings
- Competitors: Labcorp, Mayo Clinic Laboratories
- Routine Blood Tests: Includes basic metabolic panels, complete blood counts, and lipid profiles. Competitors include Labcorp and Mayo Clinic Laboratories. Market share is implicitly reflected in overall market share (see 'Competitors' section).
- COVID-19 Testing: Offered PCR and antibody testing services during the pandemic, contributing substantially to revenue. Competitors include Labcorp and various hospital labs. Market share is implicitly reflected in overall market share (see 'Competitors' section).
- Competitors: Labcorp, Various Hospital Labs
- Advanced Diagnostics: Encompasses specialized tests for cancer, cardiovascular disease, and neurological disorders. Competitors include Exact Sciences and Myriad Genetics. Market share is implicitly reflected in overall market share (see 'Competitors' section).
- Competitors: Exact Sciences, Myriad Genetics
Market Dynamics
Industry Overview
The clinical laboratory services industry is experiencing growth driven by an aging population, increasing prevalence of chronic diseases, and advancements in diagnostic technologies. It's a competitive landscape with consolidation trends.
Positioning
Quest Diagnostics is one of the two largest players in the US clinical lab market, possessing economies of scale, extensive network of patient service centers, and established relationships with payers and providers. It has a strong brand reputation.
Total Addressable Market (TAM)
The US clinical laboratory services market is estimated to be worth over $80 billion. Quest Diagnostics' TAM is related to this total, and they are positioned to capture a significant portion through testing and diagnostic services.
Upturn SWOT Analysis
Strengths
- Extensive network of patient service centers
- Strong brand recognition
- Comprehensive test menu
- Established relationships with payers
- Large data set for analytics and insights
Weaknesses
- Reliance on reimbursement rates
- Vulnerability to regulatory changes
- Competition from hospital labs
- Sensitivity to economic downturns
- Impact to COVID Testing volume reduction post-pandemic.
Opportunities
- Expanding into emerging markets
- Developing new diagnostic technologies
- Partnering with healthcare providers
- Increasing focus on direct-to-consumer testing
- Leveraging data analytics for personalized medicine
Threats
- Decreasing reimbursement rates
- Increased competition from other labs
- Regulatory changes affecting testing procedures
- Economic downturn impacting healthcare spending
- Cybersecurity threats and data breaches
Competitors and Market Share
Key Competitors
- LH
- DGX
- CVS
Competitive Landscape
Quest Diagnostics competes primarily with Labcorp in the national market. Other competitors include regional labs, hospital labs, and specialized testing companies. Quest Diagnostics benefits from its scale and brand recognition but faces pressure on pricing.
Major Acquisitions
Cleveland HeartLab
- Year: 2017
- Acquisition Price (USD millions): 146
- Strategic Rationale: To expand Quest's cardiovascular disease testing portfolio.
Growth Trajectory and Initiatives
Historical Growth: Quest Diagnostics has experienced moderate growth historically, driven by acquisitions and organic growth in diagnostic testing volumes.
Future Projections: Future growth depends on market trends, technological advancements, and strategic initiatives. Analyst estimates would be needed for specific projections.
Recent Initiatives: Recent initiatives could include acquisitions, partnerships, and investments in new technologies or testing platforms.
Summary
Quest Diagnostics is a strong player in the diagnostic testing market, leveraging its scale and brand. It benefits from an aging population and increasing chronic diseases. Challenges include reimbursement pressures and competition. Strategic acquisitions and new technologies will be important for future growth.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market data is dynamic, and actual results may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Quest Diagnostics Incorporated
Exchange NYSE | Headquaters Secaucus, NJ, United States | ||
IPO Launch date 1996-12-17 | Chairman, CEO & President Mr. James E. Davis | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 45000 | Website https://www.questdiagnostics.com |
Full time employees 45000 | Website https://www.questdiagnostics.com | ||
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, emerging retail healthcare providers, pharmaceutical companies and insurers, commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.